Visiongain has launched a new report on the Global Pre-Filled Syringes Market Report 2022-2032. It includes Pre-Filled Syringes and Forecasts Market Segment by Type, (Conventional Prefilled Syringes, Safety Prefilled Syringes) , Market Segment by Design, (Single Chambered, Dual Chambered, Customized Prefilled Syringes) Market Segment by End-User, (Hospitals and Clinics, Home Care Settings, Research Laboratories, Pharma & Biotech Companies, Other end-User), Market Segment by Application, (Diabetes, Ophthalmology, Anaphylaxis, Cancer, Thrombosis, Ophthalmology) Market Segment by Material, (Glass, Plastic, Elastomer, Stainless Steel) PLUS COVID-19 Impact Analysis and Recovery Pattern Analysis (V-shaped, W-shaped, U-shaped, L-shaped) Profiles of Leading Companies, Region and Country.

The global pre-filled syringes market was valued at US$2,448 million in 2021 and is projected to grow at a CAGR of 7.9% during the forecast period 2022-2032 to reach the market value of US$5,590 million by 2032.

Download Exclusive Sample of Report @ https://www.visiongain.com/report/pre-filled-syringes-market-2022/#download_sampe_div

Growth in Home Based Health Care Market to propel the Pre-Filled Syringes Market

Rise in geriatric population, as well as the increase incidence of chronic diseases such as Cancer, Diabetes and Musculoskeletal disorders such as arthritis are likely to drive market expansion. Moreover, the recent pandemic of COVID-19 has compelled the healthcare workers and the patients to self-administer medicines from home care set-ups. Governments and health groups are concerned about rising treatment costs and are working to control them. Home health care is a less expensive option than hospitalization. According to a Commonwealth Fund report, "hospital at home" programs allow patients to obtain acute care at home with fewer problems and saving of 30% on the total expenditure. The rising prevalence of certain diseases that necessitate long-term care, such as Alzheimer's disease and dementia, is predicted to boost home-based care. In addition, people are becoming increasingly aware of home care services and equipment that can help with these problems. Portable gadgets, such as heart rate monitors, respiratory assistance, and blood glucose monitors, have enhanced the efficiency and effectiveness of lifestyle disease home care, simultaneously boosting the demand for pre-filled syringes market.

How has COVID-19 had a significant negative impact on the Pre-Filled Syringes Market?

With COVID-19 pandemic, the prefilled syringes business has witnessed a significant growth. Since the outbreak of the pandemic, global market players involved in the development of the prefilled syringes market across the globe have increased their investment in raw materials and resources owing to the rise in demand for home based healthcare services.

Health care professionals have responded to new and varied ways of delivering the appropriate quantity of care by embracing telemedicine, which helps to reduce face-to-face interaction, as a part of the market demand. Furthermore, the industry is embracing new methods for maintaining virtual healthcare and digital technologies to meet the demand of patients who are unable to visit medical facilities and have the risk of infection. The increasing role of community and individual pharmacists in the management of chronic conditions, as well as the promotion of medication adherence during the COVID-19 pandemic outbreak has eased the burden of healthcare systems. Furthermore, increased investments from public authorities, particularly governments across the globe, are expected to boost the prefilled syringes market and will also witness development and expansion potential through 2032. Becton, Dickinson and Company (US), Gerresheimer (Germany), West Pharmaceutical Services, Inc. (US), Baxter International Inc. (US), Ompi (Italy), Catalent, Inc. (US), Weigao Group (China), Vetter Pharma International GmbH (Germany) and Nipro Corporation (Japan) are some of the leading participants in the Prefilled Syringes market

How this Report Will Benefit you?

Visiongain’s 502+ page report provides 357 tables and 344 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the global pre-filled syringes market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Pre-Filled Syringes. Get the financial analysis of the overall market and different segments including type, drug, material, end-user and capture higher market share. We believe that high opportunity remains in this fast-growing pre-filled syringes market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report would help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

What are the current market drivers?

Increase Adoption of Injectable Drug

Prefilled syringes, auto-injectors, pen injectors, and needle-free devices have come a long way from traditional syringes with vials. These sophisticated devices have become the preferred method of administering medications via parenteral infusion. In particular, during the last few years, demand for prefilled syringes has skyrocketed. This method of drug delivery is presently being used by an increasing number of medical facilities. Prefilled syringes aren't just popular in hospitals but self-injecting patients who want a simpler and safer way to administer their medications at home prefer them as well. The increased use of parenteral medications, particularly biologics, for the treatment of diseases and chronic disorders including multiple sclerosis and rheumatoid arthritis has compelled drug and packaging makers to develop more sophisticated container closure and drug delivery systems. Pharmaceutical companies are now packaging a variety of injectable medications and vaccines in prefilled syringe design in response to this growing trend. Prefilled syringes are now available for over 100 injectable medicinal items, and a growing number of pipeline pharmaceuticals are slated for this delivery route.

Many of the top pharmaceutical companies produce prefilled syringes as the preferred delivery mechanism and have minimum of fifty injectable medications and vaccines in this design. Outside of the traditional domains of anticoagulants and vaccines, prefilled syringes are being used across a wide range of therapeutic sectors. Prefilled syringes have several advantages for pharmaceutical companies, including reducing drug waste, extending product life, and boosting market share. The prefilled safety syringe market has grown at an exponential rate in recent years as a result of this trend toward self-care, enabling improved ease-of-use and safety for all caregivers and self-administering patients in non-clinical settings. Clinical trials and the adoption of novel drug delivery technologies are also likely to drive market expansion. The current COVID-19 epidemic, which has increased the number of casualty cases in medical facilities around the world, is also helping to expand the industry.

Over the last ten years, advances in glass manufacturing have resulted in improved prefill syringes. Glass-forming technologies have improved, allowing for more precise control of syringe barrel dimensions, fewer flaws, and improved barrel strength. Through the invention of diving nozzle technology for improved control of silicone-oil distribution, advancements in the syringe production process have addressed difficulties such as tungsten residues and optimal siliconisation of syringe barrels. Prefill syringe quality was also enhanced with automated processes for packaging syringes in nests, tubs, and bags. Pharmacies now have a wider range of options owing to the development of polymer prefill syringes.

Get Detailed TOC @ https://www.visiongain.com/report/pre-filled-syringes-market-2022/#download_sampe_div

Where are the market opportunities?

Increase in Demand for Injectable Drug in Prefilled Form

Syringes with prefilled needles have been around for almost two decades. In comparison to the US market, which is still in its nascent phase, the European market for prefilled syringes is more mature. In recent years, however, as the pharmaceutical industry has evolved, the market for prefilled syringes has witnessed steady expansion. Prefilled syringes accounted for a market of US$923 million for Europe in 2021 and is expected to grow at an annual rate of 8-10 percent from 2022-2032. As a result, manufacturers of prefilled syringes have adapted to this rising demand, new requirements, and more sophisticated drug delivery methods. Significant R&D in the field of prefilled syringes has been observed especially with respect to package injectable medications and diluents, prefilled syringes are now considered extremely helpful. Vaccines, blood stimulants, therapeutic proteins, erythro-proteins, interferons, and rheumatoid arthritis are only a few of the categories of medications packaged in prefilled syringes. Prefilling is recommended for many new products which have parenteral mode of drug administration.

Rising Preference for Biotechnology Drugs and The Emerging Biotech Sector

Prefilled injectors are primarily used in hospital emergency departments and for the treatment of certain chronic conditions. These injectable devices are suitable containers for vaccinations and other biotech medications, which would otherwise become unstable and react with the container's substance, altering the drug's potency. During the forecast period, rising demand for biotechnology drugs and a developing biotech sector with more opportunities are expected to have a positive impact on market growth. Medical device manufacturers normally follow the Quality System Standard, while drug and biologic producers generally follow the current Good Manufacturing Practice regulation (CGMP) (QSR). Elements of the CGMP regulation may be added to an existing QSR-based quality system to assure full compliance with quality system standards for a single-entity or kit combination product like prefilled syringes that combines drug and device constituent parts, and vice versa.

The major players operating in the pre-filled syringes market are Becton, Dickinson And Company, West Pharmaceutical Services, Inc., Catalent, INC., Nipro Corporation, Baxter International Inc. Ypsomed, Terumo Corporation, Dätwyler Holding Inc., Biocon Ltd, Gerresheimer AG, Cardinal Health, Fresenius SE & Co. KGaA, AptarGroup Inc. Schott AG, Elcam Medical, Haselmeier, Micsafe Medical Group, Owen Mumford Ltd, MedXL Inc., B. Braun Medical Inc., These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Pre-filled syringes market and leading companies. You will find data, trends and predictions.

Find more Visiongain research reports on Pharma Medical Devices; click on the following links:

Medical Device Contract Manufacturing Market

Artificial Intelligence (AI) in Drug Discovery Market

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: dev.visavadia@visiongain.com

Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports mean that you can have a bespoke piece of market intelligence customized to your very own business needs.

Contact: Dev Visavadia PR at Visiongain Reports Limited Tel: + 44 0207 336 6100 Email: dev.visavadia@visiongain.com

The European Medicines Agency (EMA) has validated Aeglea BioTherapeutics Inc's (NASDAQ: AGLE) marketing application seeking approval for pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D). Arginase deficiency is an inherited disorder that causes the amino acid arginine (a building block of proteins) and ammonia to accumulate gradually in the blood. Ammonia, formed when proteins are broken down in the body, is toxic if levels become too high. Related: Aeglea BioTherapeutics Shares

Yahoo Finance's Brian Cheung discusses reports that a depression drug from Axsome Therapeutics has gotten FDA clearance.

The Biden administration is planning to stop paying for Covid vaccines and treatments, a move that could buoy some Covid stocks.

U.S. based monkeypox vaccine manufacturer targets December for first batch of doses for delivery.

The U.S. government asks Bavarian Nordic, the sole manufacturer of a monkeypox vaccine, to find new partners.

As one of the leading genetic medicine companies on the planet, Sarepta Therapeutics is on the forefront of many nerdy advances. It was the first drug developer to earn U.S. Food and Drug Administration (FDA) approval for products treating Duchenne muscular dystrophy (DMD), a rare genetic disorder impacting muscle development. Meanwhile, Sarepta Therapeutics currently boasts over 37 pipeline programs, including 21 assets in gene therapy alone.

NBC News Chief Foreign Correspondent Richard Engel announced Thursday that his son Henry, 6, has died. “Our beloved son Henry passed away.

Get ready for a big change in how the U.S. will pay for COVID-19 vaccines and treatments. The Department of Health and Human Services is expected to hold a meeting later this month with drug makers, pharmacies, and state health departments to discuss moving coverage of pandemic therapies away from the U.S. government and into a commercial market, according to The Wall Street Journal. Arpa Garay, Moderna’s (MRNA) chief commercial officer, told investors on a recent earnings call that the company is already preparing for the evolution of the COVID-19 vaccine market.

The drug, which can take effect within a week, uses a different mechanism than traditional treatments for depression.

By Mark Gilman -- Benzinga

Verve’s effort to lower patients’ levels of bad cholesterol with a single injection is gradually making clinical progress and would be a significant upgrade from statins and other medicines currently available.

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT Second Quarter 2022 Operational and Financial Results On August 16, 2022, BioLineRx Ltd. (NASDAQ:BLRX) reported 2Q:22 operational and financial results in a press release concurrent with the filing of Form 6-K . A conference call and webcast were hosted later that morning. Key highlights since the previous update in May

These three first aid essentials will keep everyone healthy and feeling good while you enjoy the summer.

The FDA approved a first-of-its-kind treatment from Bluebird Bio that represents a potential cure for a rare blood disorder at a price of $2.8 million per patient.

Somerville gene therapy firm bluebird bio Inc. has scored its first approval from the U.S. Food and Drug Administration following its business split late last year.

New Zealand's Medsafe has granted expanded provisional approval for Novavax Inc's (NASDAQ: NVAX) Nuvaxovid (NVX-CoV2373) COVID-19 vaccine in adolescents aged 12 through 17. The provisional approval was based on data from the ongoing pediatric expansion of the Phase 3 PREVENT-19 trial of 2,247 adolescents aged 12 through 17. In the pediatric expansion, Nuvaxovid achieved its primary effectiveness endpoint and demonstrated 80% overall clinical efficacy when the Delta variant was predominant. Relat

The Pensacola community has been mourning the death of SCI business director Rodney Jackson from Vibrio. Here's what to know about the bacteria.

Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now?

RedHill's (RDHL) RHB-204 gets Orphan Drug designation from the European Commission for the treatment of nontuberculous mycobacteria (NTM) disease

BridgeBio Pharma Inc (NASDAQ: BBIO) has dosed the first patient in its Phase 1 trial of BBP-671, an investigational oral therapy for conditions caused by coenzyme A (CoA) deficiencies, including propionic acidemia (PA), methylmalonic acidemia (MMA), and pantothenate kinase-associated neurodegeneration (PKAN). PA and MMA are rare metabolic disorders in which the body cannot properly break down certain proteins and lipids (fats). BBP-671 is an investigational oral therapy intended to increase CoA